sunbet

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
¼±ÐÔñ²ðﶯÎïÄ£×Ó
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > Éñ¾­ÏµÍ³Ä£×Ó > ¼±ÐÔñ²ðﶯÎïÄ£×Ó

Ç°ÑÔ

ñ²²¡(epilepsy)ÊÇÒ»ÖÖÒÔ´óÄÔ¾Ö²¿²¡ÔîÍ»·¢ÐÔµÄÒ»´Î¸ßƵ·Åµç²¢ÏòÖÜΧ×éÖ¯À©É¢ÎªÌØÕ÷µÄ´óÄÔ¹¦Ð§ÕÏ°­£¬Í¬Ê±Åãͬ¶ÌÔݵÄÔ˶¯¡¢¸ÐÊÜ¡¢ÒâʶºÍ×ÔÖ÷Éñ¾­¹¦Ð§Òì³££¬ÄÔµçͼÓÐÏÔ×Å¸Ä±ä ¡£WHOÓÚ2005ÄêÐû²¼µÄ×ÊÁÏÏÔʾȫÌìÏÂÓÐ5000ÍòµÄñ²²¡»¼Õߣ¬Æ½¾ùÄê·¢²¡ÂÊΪ0.5‰~1‰ ¡£Éæ¼°ñ²ðïµÄÑо¿Èçϸ°ûµçÐÄÀí¼Í¼¡¢Ï¸°ûÄÚ΢ÒòËØÆÊÎöÒÔ¼°×é֯ѧ׷×ÙÊÖÒյȣ¬¶¼²»Ì«¿ÉÄÜÖ±½ÓÔÚÈËÄÔÄÚÀï¾ÙÐÐ £»¿¹ñ²²¡Ò©ÎïµÄ¿ª·¢ºÍÑо¿£¬Ò²²»¿ÉÄÜÈÝÒ×ÔÚÈËÌåÖоÙÐÐ ¡£Òò´Ë£¬ÔÚÑо¿ñ²ðﲡÀí²¡Éú¸Ä±äºÍɸѡ¿¹ñ²ðïÒ©Îïʱ£¬ÍùÍùÒÀÀµÓÚ¶¯ÎïʵÑé ¡£

Ò»¸öÀíÏëñ²ðïÄ£×ÓÓ¦¾ßÓкÍÈËÀàñ²ðïÏàËƵı¬·¢¡¢Éú³¤µÄÀú³Ì£¬ÖÁÉÙÓ¦¾ß±¸ÈçÏÂÌØÕ÷£º¢Ù¾ßÓÐÖîÈçÉñ¾­ÔªÉ¥Ê§¡¢½ºÖÊϸ°ûÔöÉú¡¢Öáͻ˿״ѿÉúºÍÍ»´¥ÖØÐÞµÈÓëÈËÀàñ²²¡ÏàËƵIJ¡Àíѧת±ä £»¢ÚÔÚ³õʼ´Ì¼¤ºÍ×Ô¾õÐÔñ²²¡±¬·¢Ö®¼äÓнÏΪÀο¿µÄDZÔÚÆÚ£¨ÊýÌìÖÁÊýÖÜ£© £»¢ÛÄ£×ÓÄÜÔÚһ׼ʱ¼äÄÚ¼á³Ö´óÄÔÉñ¾­ÔªÐË·ÜÐÔÒ»Á¬Ôö¸ß ¡£

Ö±ÖÁÏÖÔÚ£¬ÉÐÎÞÒ»ÖÖ¶¯Îïñ²ðïÄ£×ÓÄܹ»ÍêÈ«¸´ÖÆÈËÀàñ²ðï ¡£ÁíÍ⣬ÓÉÓÚñ²²¡ÁÙ´²±¬·¢ÐÎʽ¶àÑùµÄÌص㣬²»¿É½öÓÃÒ»ÖÖÄ£×Ó¾ÙÐÐñ²²¡Ñо¿ ¡£ñ²ðﶯÎïÄ£×ÓµÄÑ¡ÔñÈ¡¾öÓÚ°üÀ¨Ñо¿Ä¿µÄ¡¢Ä£×Ó¶ÔÓ¦µÄÁÙ´²±¬·¢ÀàÐÍ¡¢¶ÔÄ£×ÓµÄÊìϤˮƽ¼°Ä£×ÓÖƱ¸µÄÄÑÒ×µÈÒòËØ ¡£

ƾ֤ÓÕ·¢ñ²ðïµÄʱ³Ì¡¢ÒÅ´«Åä¾°ºÍÒ©Îï¶Ô¿¹ÐÔµÈÌص㣬ñ²ðïµÄ¼²²¡¶¯ÎïÄ£×Ó¿É·ÖΪ¼±ÐÔñ²²¡Ä£×Ó¡¢ÂýÐÔñ²²¡Ä£×Ó¡¢×Ô¾õÐÔñ²²¡Ä£×Ó ¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯ÎСÊó¡¢´óÊó

¡¾ÔìÄ £»úÖÆ¡¿£º

ÔÚ¶¯ÎïÁ½¶ú»òÑÛÇò²¿Î»°²Åŵ缫£¬ÒÔÇ¿µçÁ÷ͨ¹ýµç¼«¶ÔÄÔ²¿¾ÙÐжÌʱ¼ä´Ì¼¤£¬Ê¹¶¯Îﱬ·¢Ë«ºóÖ«Ç¿Ö±ÐÔ¾ªØÊ ¡£

¡¾Ä£×ÓÒªÁì¡¿£º

ÓõçÐÝ¿ËÒÇ»òÒ©ÀíÐÄÀíʵÑé¶àÓÃÒÇ£¬µ¼ÏßÒý³ö½»Á÷µç£¬½«Êä³öÏßÉÏÅþÁ¬åŠÓã¼Ð£¬ÒÔÐÄÀíÑÎˮʪÈóºó£¬»®·Ö¼ÐÓÚСÊó»ò´óÊóË«¶ú£¬»òÓÃÉÔ°¼Ô²ÅÌ×´½ÇĤµç¼«½Ó´¥Ë«½ÇĤ£¨½ÇĤÓö¡¿¨ÒòÂé×í£©£¬Ë漴ͨµç£¬¼´¿ÉʹСÊó»ò´óÊ󱬷¢µä·¶µÄÇ°Ö«ÓÞÃÁ¡¢ºóÖ«ÉìÖ±µÄÇ¿Ö±ÐÔ¾ªØÊ ¡£µç´Ì¼¤²ÎÊýÒ»Ñùƽ³£ÎªÐ¡Êó50mA¡¢´óÊó150mA¡¢60Hz¡¢80~120V£¨´óÊóÓÃ180V)£¬´Ì¼¤Ê±¼äΪ0.2~03Ãë ¡£¾ªØÊÀú³Ì¿É·ÖΪDZÔÚÆÚ¡¢Ç¿Ö±ÆÚ¡¢ÕóÂÎÆÚ¼°¾ªØʺóÒÖÖÆÆÚ ¡£ÊÓ²ìÖ¸±ê£ºÒÔ¶¯ÎïÊÇ·ñ·ºÆðºó֫ǿֱΪÊÓ²ìÖ¸±ê£¬ÈôijÖÖÒ©ÎïÄÜ×èÖ¹Æ䱬·¢£¬ËµÃ÷¸ÃÒ©¾ßÓп¹MES×÷Óà ¡£

¡¾Ä£×ÓÌص㡿£º

MESÄ£×ÓÊÇʹÓý϶àÇüÑо¿½ÏΪ͸³¹µÄÄ£×ÓÖ®Ò» ¡£³£ÓÃÓÚÄ£ÄâÈËÀàµÄÇ¿Ö±ÕóÂÎñ²ðï´ó±¬·¢£¬²¢ÓÃÓÚ¿¹Ç¿Ö±£­ÕóÂÎñ²ðï´ó±¬·¢µÄÒ©Îïɸѡ ¡£¾­µäµÄ¿¹ñ²²¡Ò©Îï±½Í×Ó¢ÄƾÍÊÇͨ¹ýMESÄ£×Ó·¢Ã÷µÄ ¡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

MESñ²ðïÄ£×ÓÖƱ¸ÒªÁì¼òÆÓ£¬ÇÒÓнÏÁ¿¸ßµÄɸѡ¿¹ñ²²¡»¯ºÏÎïµÄЧÂÊ ¡£¼±ÐÔñ²ðïÄ£×ÓÒ²ÊÇÓÐÆäȱ·¦Ö®´¦µÄ£ºMESÄ£×Ó¶Ô×÷ÓÃÓÚÀë×ÓÐÍͨµÀµÄÒ©Îï×÷ÓÃЧ¹ûÏÔÖø£¬¿ÉÄܺöÂÔÁËÆäËûÓп¹ñ²ðï×÷ÓõÄÒ©ÎÈç°±»ù¼ºËá¡¢àç¼Ó±öµÈ£© £»MESÄ£×Ó²»ÊʺϿ¹²¿·Öñ²ðﱬ·¢µÄÒ©ÎïµÄɸѡ£¬È磬MESÄ£×ÓÌáÐÑN£­¼×»ù£­D-Ì춬°±ËáÊÜÌå(N-methyl-D-aspartic acid, NMDA)ÊÜÌåµÄÞ׿¹¼ÁÓÐÓ㬿ÉÊǸÃÞ׿¹¼ÁÔÚµãȼ(kindling)Ä£×Ó¼°ÁÙ´²ÊÔÑéÖж¼Ã»ÓÐÃ÷È·µÄ¿¹ñ²ðï×÷Óà ¡£ÐèҪǿµ÷µÄÊÇ£¬¼±ÐÔñ²ðïÄ£×Ó²»¿ÉÄ£ÄâÈËÀàñ²ðﱬ·¢Éú³¤µÄÕû¸öÀú³Ì£¬¸ü²»¿ÉÄ£ÄâÄÑÖÎÐÔñ²ðï¡¢Ò©Îï¶Ô¿¹ÐÔñ²ðïµÄ²¡ÀíÐÄÀí¸Ä±äÀú³Ì ¡£

 

 

²Î¿¼ÎÄÏ×£º

1.Andrè V, Dube C, Francois J, et al. Pathogenesis and pharmacology of epilepsy in the lithium-pilocarpine model. Epilepsia,2007,48 (Suppl 5):41-47

2.Gareri P, Condorelli D, Bellua.rdo N, el al. Antiabsence effects of carbenoxolone in two genetic animal models of absence epilepsy (WAG/Rij rats and lh/lh mice).Neuropharmacology, 2005, 49 (4):551-563

3.Holmes GL. Animal model studies application to human patients. Neurology, 2007, 69 (24 Suppl 3): S28-32

4.Jefferys JG. Models and mechanisms of experimental epilepsies. Epilepsia, 2003, 44 (Suppl 12):44-50

5.Löscher W,Leppik IE. Critical re-evaluation of previous preclinical strategies for the cliscovery and the development of new anliepileplic drugs. Epilepsy Res, 2002, 50 (1-2):17-20

6.Löscher W,Schmidt D.Stralegies in aatiepileptic drug development: is rational drug design superior to random screening and structural variation?Epilepsy Res, 1994, 17 (2):95-134

7.Wang Y, Zhou D, Wang B, el al. A kindling model of pharmacoresislanl temporal lobe epilepsy in SpragueDawley rats induced by Coriaria lactone and its possible mechanism. Epilepsia,2003,44(4):475-488

8.White HS. Preclinical development of antiepileptic drugs: past, present, and future directions. Epilepsia, 2003, 44 (Suppl 7):2-8

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Ä£×ÓĿ¼
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > Éñ¾­ÏµÍ³Ä£×Ó > ¼±ÐÔñ²ðﶯÎïÄ£×Ó
¼±ÐÔñ²ðﶯÎïÄ£×Ó

Ç°ÑÔ

ñ²²¡(epilepsy)ÊÇÒ»ÖÖÒÔ´óÄÔ¾Ö²¿²¡ÔîÍ»·¢ÐÔµÄÒ»´Î¸ßƵ·Åµç²¢ÏòÖÜΧ×éÖ¯À©É¢ÎªÌØÕ÷µÄ´óÄÔ¹¦Ð§ÕÏ°­£¬Í¬Ê±Åãͬ¶ÌÔݵÄÔ˶¯¡¢¸ÐÊÜ¡¢ÒâʶºÍ×ÔÖ÷Éñ¾­¹¦Ð§Òì³££¬ÄÔµçͼÓÐÏÔ×Å¸Ä±ä ¡£WHOÓÚ2005ÄêÐû²¼µÄ×ÊÁÏÏÔʾȫÌìÏÂÓÐ5000ÍòµÄñ²²¡»¼Õߣ¬Æ½¾ùÄê·¢²¡ÂÊΪ0.5‰~1‰ ¡£Éæ¼°ñ²ðïµÄÑо¿Èçϸ°ûµçÐÄÀí¼Í¼¡¢Ï¸°ûÄÚ΢ÒòËØÆÊÎöÒÔ¼°×é֯ѧ׷×ÙÊÖÒյȣ¬¶¼²»Ì«¿ÉÄÜÖ±½ÓÔÚÈËÄÔÄÚÀï¾ÙÐÐ £»¿¹ñ²²¡Ò©ÎïµÄ¿ª·¢ºÍÑо¿£¬Ò²²»¿ÉÄÜÈÝÒ×ÔÚÈËÌåÖоÙÐÐ ¡£Òò´Ë£¬ÔÚÑо¿ñ²ðﲡÀí²¡Éú¸Ä±äºÍɸѡ¿¹ñ²ðïÒ©Îïʱ£¬ÍùÍùÒÀÀµÓÚ¶¯ÎïʵÑé ¡£

Ò»¸öÀíÏëñ²ðïÄ£×ÓÓ¦¾ßÓкÍÈËÀàñ²ðïÏàËƵı¬·¢¡¢Éú³¤µÄÀú³Ì£¬ÖÁÉÙÓ¦¾ß±¸ÈçÏÂÌØÕ÷£º¢Ù¾ßÓÐÖîÈçÉñ¾­ÔªÉ¥Ê§¡¢½ºÖÊϸ°ûÔöÉú¡¢Öáͻ˿״ѿÉúºÍÍ»´¥ÖØÐÞµÈÓëÈËÀàñ²²¡ÏàËƵIJ¡Àíѧת±ä £»¢ÚÔÚ³õʼ´Ì¼¤ºÍ×Ô¾õÐÔñ²²¡±¬·¢Ö®¼äÓнÏΪÀο¿µÄDZÔÚÆÚ£¨ÊýÌìÖÁÊýÖÜ£© £»¢ÛÄ£×ÓÄÜÔÚһ׼ʱ¼äÄÚ¼á³Ö´óÄÔÉñ¾­ÔªÐË·ÜÐÔÒ»Á¬Ôö¸ß ¡£

Ö±ÖÁÏÖÔÚ£¬ÉÐÎÞÒ»ÖÖ¶¯Îïñ²ðïÄ£×ÓÄܹ»ÍêÈ«¸´ÖÆÈËÀàñ²ðï ¡£ÁíÍ⣬ÓÉÓÚñ²²¡ÁÙ´²±¬·¢ÐÎʽ¶àÑùµÄÌص㣬²»¿É½öÓÃÒ»ÖÖÄ£×Ó¾ÙÐÐñ²²¡Ñо¿ ¡£ñ²ðﶯÎïÄ£×ÓµÄÑ¡ÔñÈ¡¾öÓÚ°üÀ¨Ñо¿Ä¿µÄ¡¢Ä£×Ó¶ÔÓ¦µÄÁÙ´²±¬·¢ÀàÐÍ¡¢¶ÔÄ£×ÓµÄÊìϤˮƽ¼°Ä£×ÓÖƱ¸µÄÄÑÒ×µÈÒòËØ ¡£

ƾ֤ÓÕ·¢ñ²ðïµÄʱ³Ì¡¢ÒÅ´«Åä¾°ºÍÒ©Îï¶Ô¿¹ÐÔµÈÌص㣬ñ²ðïµÄ¼²²¡¶¯ÎïÄ£×Ó¿É·ÖΪ¼±ÐÔñ²²¡Ä£×Ó¡¢ÂýÐÔñ²²¡Ä£×Ó¡¢×Ô¾õÐÔñ²²¡Ä£×Ó ¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯ÎСÊó¡¢´óÊó

¡¾ÔìÄ £»úÖÆ¡¿£º

ÔÚ¶¯ÎïÁ½¶ú»òÑÛÇò²¿Î»°²Åŵ缫£¬ÒÔÇ¿µçÁ÷ͨ¹ýµç¼«¶ÔÄÔ²¿¾ÙÐжÌʱ¼ä´Ì¼¤£¬Ê¹¶¯Îﱬ·¢Ë«ºóÖ«Ç¿Ö±ÐÔ¾ªØÊ ¡£

¡¾Ä£×ÓÒªÁì¡¿£º

ÓõçÐÝ¿ËÒÇ»òÒ©ÀíÐÄÀíʵÑé¶àÓÃÒÇ£¬µ¼ÏßÒý³ö½»Á÷µç£¬½«Êä³öÏßÉÏÅþÁ¬åŠÓã¼Ð£¬ÒÔÐÄÀíÑÎˮʪÈóºó£¬»®·Ö¼ÐÓÚСÊó»ò´óÊóË«¶ú£¬»òÓÃÉÔ°¼Ô²ÅÌ×´½ÇĤµç¼«½Ó´¥Ë«½ÇĤ£¨½ÇĤÓö¡¿¨ÒòÂé×í£©£¬Ë漴ͨµç£¬¼´¿ÉʹСÊó»ò´óÊ󱬷¢µä·¶µÄÇ°Ö«ÓÞÃÁ¡¢ºóÖ«ÉìÖ±µÄÇ¿Ö±ÐÔ¾ªØÊ ¡£µç´Ì¼¤²ÎÊýÒ»Ñùƽ³£ÎªÐ¡Êó50mA¡¢´óÊó150mA¡¢60Hz¡¢80~120V£¨´óÊóÓÃ180V)£¬´Ì¼¤Ê±¼äΪ0.2~03Ãë ¡£¾ªØÊÀú³Ì¿É·ÖΪDZÔÚÆÚ¡¢Ç¿Ö±ÆÚ¡¢ÕóÂÎÆÚ¼°¾ªØʺóÒÖÖÆÆÚ ¡£ÊÓ²ìÖ¸±ê£ºÒÔ¶¯ÎïÊÇ·ñ·ºÆðºó֫ǿֱΪÊÓ²ìÖ¸±ê£¬ÈôijÖÖÒ©ÎïÄÜ×èÖ¹Æ䱬·¢£¬ËµÃ÷¸ÃÒ©¾ßÓп¹MES×÷Óà ¡£

¡¾Ä£×ÓÌص㡿£º

MESÄ£×ÓÊÇʹÓý϶àÇüÑо¿½ÏΪ͸³¹µÄÄ£×ÓÖ®Ò» ¡£³£ÓÃÓÚÄ£ÄâÈËÀàµÄÇ¿Ö±ÕóÂÎñ²ðï´ó±¬·¢£¬²¢ÓÃÓÚ¿¹Ç¿Ö±£­ÕóÂÎñ²ðï´ó±¬·¢µÄÒ©Îïɸѡ ¡£¾­µäµÄ¿¹ñ²²¡Ò©Îï±½Í×Ó¢ÄƾÍÊÇͨ¹ýMESÄ£×Ó·¢Ã÷µÄ ¡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

MESñ²ðïÄ£×ÓÖƱ¸ÒªÁì¼òÆÓ£¬ÇÒÓнÏÁ¿¸ßµÄɸѡ¿¹ñ²²¡»¯ºÏÎïµÄЧÂÊ ¡£¼±ÐÔñ²ðïÄ£×ÓÒ²ÊÇÓÐÆäȱ·¦Ö®´¦µÄ£ºMESÄ£×Ó¶Ô×÷ÓÃÓÚÀë×ÓÐÍͨµÀµÄÒ©Îï×÷ÓÃЧ¹ûÏÔÖø£¬¿ÉÄܺöÂÔÁËÆäËûÓп¹ñ²ðï×÷ÓõÄÒ©ÎÈç°±»ù¼ºËá¡¢àç¼Ó±öµÈ£© £»MESÄ£×Ó²»ÊʺϿ¹²¿·Öñ²ðﱬ·¢µÄÒ©ÎïµÄɸѡ£¬È磬MESÄ£×ÓÌáÐÑN£­¼×»ù£­D-Ì춬°±ËáÊÜÌå(N-methyl-D-aspartic acid, NMDA)ÊÜÌåµÄÞ׿¹¼ÁÓÐÓ㬿ÉÊǸÃÞ׿¹¼ÁÔÚµãȼ(kindling)Ä£×Ó¼°ÁÙ´²ÊÔÑéÖж¼Ã»ÓÐÃ÷È·µÄ¿¹ñ²ðï×÷Óà ¡£ÐèҪǿµ÷µÄÊÇ£¬¼±ÐÔñ²ðïÄ£×Ó²»¿ÉÄ£ÄâÈËÀàñ²ðﱬ·¢Éú³¤µÄÕû¸öÀú³Ì£¬¸ü²»¿ÉÄ£ÄâÄÑÖÎÐÔñ²ðï¡¢Ò©Îï¶Ô¿¹ÐÔñ²ðïµÄ²¡ÀíÐÄÀí¸Ä±äÀú³Ì ¡£

 

 

²Î¿¼ÎÄÏ×£º

1.Andrè V, Dube C, Francois J, et al. Pathogenesis and pharmacology of epilepsy in the lithium-pilocarpine model. Epilepsia,2007,48 (Suppl 5):41-47

2.Gareri P, Condorelli D, Bellua.rdo N, el al. Antiabsence effects of carbenoxolone in two genetic animal models of absence epilepsy (WAG/Rij rats and lh/lh mice).Neuropharmacology, 2005, 49 (4):551-563

3.Holmes GL. Animal model studies application to human patients. Neurology, 2007, 69 (24 Suppl 3): S28-32

4.Jefferys JG. Models and mechanisms of experimental epilepsies. Epilepsia, 2003, 44 (Suppl 12):44-50

5.Löscher W,Leppik IE. Critical re-evaluation of previous preclinical strategies for the cliscovery and the development of new anliepileplic drugs. Epilepsy Res, 2002, 50 (1-2):17-20

6.Löscher W,Schmidt D.Stralegies in aatiepileptic drug development: is rational drug design superior to random screening and structural variation?Epilepsy Res, 1994, 17 (2):95-134

7.Wang Y, Zhou D, Wang B, el al. A kindling model of pharmacoresislanl temporal lobe epilepsy in SpragueDawley rats induced by Coriaria lactone and its possible mechanism. Epilepsia,2003,44(4):475-488

8.White HS. Preclinical development of antiepileptic drugs: past, present, and future directions. Epilepsia, 2003, 44 (Suppl 7):2-8

¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿